Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company that regularly issues news and updates about its inflammation and immunology pipeline targeting the innate immune system. This news page aggregates company press releases and third-party coverage related to INmune Bio’s DN-TNF platform, CORDStrom™ mesenchymal stromal cell platform, and INKmune® natural killer cell priming platform.
Readers can find updates on XPro™ (XPro1595, pegipanermin), a selective soluble TNF neutralizer that the company is developing for neurological diseases driven by chronic inflammation. Recent news has highlighted Phase 2 MINDFuL trial results in early Alzheimer’s disease with inflammatory biomarkers, neuroimaging analyses using advanced MRI techniques, and manuscript submissions to peer-reviewed journals. The company also reports on scientific presentations at conferences such as the Clinical Trials on Alzheimer’s Disease (CTAD) meeting and the Alzheimer’s Association International Conference.
News related to the CORDStrom™ cell therapy platform includes clinical and manufacturing milestones in recessive dystrophic epidermolysis bullosa (RDEB), such as completion of a blinded randomized trial, pilot-scale commercial manufacturing runs at a cell and gene therapy manufacturing center in the United Kingdom, and intellectual property developments. INmune Bio also issues updates on participation in industry events and panels focused on dermatologic rare diseases and cell therapy manufacturing.
For the INKmune® platform, news items cover progress in the CaRe PC Phase I/II trial in metastatic castration-resistant prostate cancer, including reports that the trial met its primary and certain secondary endpoints, safety observations, and biomarker findings related to NK cell activation. Corporate news, including financing transactions, management changes, and special stockholder meetings, is also disclosed through regular press releases and corresponding SEC filings. Investors and researchers can use this page to follow INMB news on clinical data, regulatory plans, manufacturing scale-up, and corporate developments.
INmune Bio announces the initiation of its first patient treatment in a Phase 1 clinical trial of INKmune, targeting high-risk myelodysplastic syndrome (MDS). This trial will assess safety, tolerability, and clinical response in MDS patients, a serious condition with no known cure. INKmune aims to enhance the activity of dysfunctional natural killer (NK) cells in patients. Initial findings indicate promising potential for treating MDS and possibly solid tumors. The Phase 1 study will enroll nine patients under a 3x3 dose escalation protocol.
On June 14, 2021, INmune Bio (NASDAQ: INMB) announced a $15 million credit facility with Silicon Valley Bank to fund the buyout of an option held by Xencor, Inc. for $18.3 million. This move eliminates the potential dilution of approximately 2.1 million shares. INmune has made significant progress in developing XPro1595, a treatment for neuroinflammation in conditions like Alzheimer’s. The company is focused on launching Phase 2 trials for XPro1595 later this year, following positive data earlier this year regarding its Alzheimer's application.
INmune Bio (NASDAQ: INMB) has received USAN approval for the generic name Pegipanermin for its lead candidate XPro1595. CEO RJ Tesi stated that this milestone marks the transition from experimental to advanced development, with plans for Phase 2 trials targeting Alzheimer’s disease and Treatment Resistant Depression. The company previously reported positive Phase 1b data showing reduced biomarkers of neuroinflammation in Alzheimer's patients. Pegipanermin utilizes a unique TNF neutralization technology, differentiating it from existing therapies.
INmune Bio (NASDAQ: INMB) announced that CEO RJ Tesi will present at the Alzheimer Disease Panel on May 26, 2021. The event, hosted by M-Vest and presented by Maxim Group LLC, features a panel discussion on advancements in Alzheimer’s drug development, including recent findings about donanemab and the upcoming June 7 PDUFA action date for aducanumab. The panel will include insights from various healthcare experts and companies like Cassava Sciences (SAVA) and Vivoryon Therapeutics (VVY). Join the webinar at 11:00 AM ET for key discussions in the field.
INmune Bio reported its Q1 2021 financial results and provided key business updates. The company is progressing in its Phase I trial of XPro1595 for Alzheimer's disease, showing promising interim results that support a Phase II trial later this year. Additionally, they began screening for a Phase I trial of INKmune for high-risk myelodysplastic syndrome. Financially, INmune raised approximately $29 million through an ATM agreement, but recorded a net loss of $4.6 million for the quarter. The company has $45.3 million in cash with no debt.
INmune Bio (NASDAQ: INMB) will host a conference call on May 5, 2021, at 4:30 PM ET, to discuss its first-quarter results for the period ending March 31, 2021, and provide a corporate update. The call can be accessed by dialing 1-877-407-0784 (or 1-201-689-8560 for international callers). A transcript will be available shortly after the call, with a replay accessible until May 12, 2021.
INmune Bio focuses on developing treatments targeting the innate immune system for various diseases.
INmune Bio, Inc. (NASDAQ: INMB) announced a participation by CEO Raymond J. Tesi, MD, in a fireside chat at the B Riley Neuroscience Conference scheduled for April 28, 2021, at 1:00 PM ET. The company focuses on developing therapies that leverage the innate immune system to combat diseases, with product platforms addressing conditions such as COVID-19, cancer, Alzheimer’s, and NASH. The event will provide an opportunity for investors to engage in virtual one-on-one meetings with the company.
INmune Bio, Inc. (NASDAQ: INMB) announced that Professor Mark Lowdell, PhD, will present at two medical meetings: the Innate Killer Digital Summit and the Festival of Biologics USA. At the Innate Killer Summit, he will discuss new findings on INKmune™, an NK-cell priming immunotherapy, which enhances the ability of NK cells to target tumors, showing superior activity compared to traditional cytokine approaches. The second presentation at the World Immunotherapy Congress will focus on improving NK-tumor cell interactions. Both events are crucial for showcasing INmune Bio's advancements in cancer immunotherapy.
INmune Bio, Inc. (NASDAQ: INMB) announced its participation in two virtual investor conferences in March 2021. The 33rd Annual Roth Virtual Conference will feature a panel discussion on therapeutics against SARS-CoV-2 on March 15, 2021, at 12:00 PM ET. The Oppenheimer 31st Annual Healthcare Conference will include a presentation by INmune Bio on March 16, 2021, at 1:10 PM ET. Interested individuals can register for both events through provided links.
INmune Bio is focused on developing treatments that leverage the innate immune system to combat diseases like COVID-19, cancer, Alzheimer’s, and NASH.
INmune Bio, Inc. (NASDAQ: INMB) reported its financial results for the year ending December 31, 2020. The company announced a net loss of approximately $12.1 million, a rise from $7.7 million in 2019. Research expenses totaled $5.9 million, while administrative costs were $6.3 million. Highlights include interim Phase 1b data showing that XPro1595 reduced neuroinflammation in Alzheimer's patients. The company raised $28.4 million through an ATM facility, strengthening its balance sheet. Upcoming milestones include Phase 2 studies for XPro1595 and Quellor.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
